Please assess the completion status of the following clinical trial:

Trial Title: Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female study subjects must be adults (≥ 6 years of age)~* Confirmed diagnosis of CF~* History of chronic infection with P.aeruginosa~* FEV1 ≥40% of predicted at Screening~* Ability to comply with study medication use, study visits and procedures~* Ability to produce 0.5 grams of sputum~Key Exclusion Criteria:~* Administration of any investigational drug within 8 weeks to Study Day 1~* Emergency room visit or hospitalization for CF or respiratory-related illness within 4 weeks prior to screening~* History of alcohol, medication or illicit drug abuse within 1 yr. to screening~* History of lung transplantation~* Female of childbearing potential who are not practicing an acceptable method of birth control or who are lactating~* Positive Pregnancy test~* Use of any anti-pseudomonal antibiotics within 28 days prior to Study Day 1~* Initiation of chronic therapy within 28 days prior to Study Day 1~* History of sputum or throat swab culture yielding Burkholderia cepacia within 2 years prior to screening~* History of mycobacterial and/or Aspergillus infection requiring treatment within 2 years prior to screening~* History of biliary cirrhosis with portal hypertension, or splenomegaly

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Arikayce™ at 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
- B (Type: PLACEBO_COMPARATOR): Matching placebo for 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
- C (Type: ACTIVE_COMPARATOR): Arikayce™ at 70 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
- D (Type: ACTIVE_COMPARATOR): Arikayce™ at 140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
- E (Type: PLACEBO_COMPARATOR): Matching placebo for 70 mg/140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).